Key result
Pravastatin fails to improve endothelium-dependent coronary vasomotion after balloon angioplasty compared to placebo.
Why the study?
Does pravastatin improve acetylcholine-induced change in mean arterial diameter in non-smoking, non-hypercholesterolaemic patients scheduled for elective balloon angioplasty?
Population
63 non-smoking, non-hypercholesterolaemic patients scheduled for elective balloon angioplasty
Comparison
Pravastatin 40 mg daily for three months vs Placebo
Design
RCT, randomised, double blind
Follow-up
3 months
Authors
Loading...
Pravastatin does not improve endothelial vasomotion after balloon angioplasty in non-hypercholesterolemic patients; confirms lack of benefit for this endpoint in an RCT.
RCT (n=72)
Double-blind
randomised
Yes
Does pravastatin improve acetylcholine-induced change in mean arterial diameter in non-smoking, non-hypercholesterolaemic patients scheduled for elective balloon angioplasty?
p-value: p=0.09
In non-hypercholesterolemic patients undergoing elective balloon angioplasty, 3 months of pravastatin therapy did not significantly improve endothelium-dependent vasomotion, although it was associated with fewer procedure-related events.
Deborah H. Bennett (2001) conducted an RCT in Coronary artery disease (n=72). Pravastatin vs. Placebo was evaluated on Acetylcholine induced change in mean arterial diameter in the dilated segment (p=0.09). Pravastatin 40 mg daily for three months did not significantly improve endothelium-dependent vasomotion in dilated or normal coronary segments after balloon angioplasty compared to placebo.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: